Skip to content
10-Q

Quarterly Report

Clearside Biomedical, Inc. CLSDQ

0000950170-25-072568

← back to feed
Filed
May 15, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 12, 2025 77.71M sh
Shares Diluted Q1 2025 · Mar 31, 2025 76.92M sh
Shares Diluted Q1 2025 · Mar 31, 2024 69.85M sh
Capex Q1 2025 · Mar 31, 2025 $9K
Capex Q1 2025 · Mar 31, 2024 $57K
Operating Cash Flow Q1 2025 · Mar 31, 2025 −$5.83M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$7.85M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $13.63M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $20.02M
Stockholders Equity Q1 2025 · Mar 31, 2025 −$45.91M
Stockholders Equity Q1 2025 · Dec 31, 2024 −$38.86M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$21.81M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$15.91M
Current Liabilities Q1 2025 · Mar 31, 2025 $5.01M
Current Liabilities Q1 2025 · Dec 31, 2024 $4.79M
Total Liabilities Q1 2025 · Mar 31, 2025 $65.58M
Total Liabilities Q1 2025 · Dec 31, 2024 $63.98M
Current Assets Q1 2025 · Mar 31, 2025 $15.96M
Current Assets Q1 2025 · Dec 31, 2024 $21.27M
Total Assets Q1 2025 · Mar 31, 2025 $19.67M
Total Assets Q1 2025 · Dec 31, 2024 $25.13M
Eps Diluted Q1 2025 · Mar 31, 2025 −$0.11
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.17
Eps Basic Q1 2025 · Mar 31, 2025 −$0.11
Eps Basic Q1 2025 · Mar 31, 2024 −$0.17
Sga Expense Q1 2025 · Mar 31, 2025 $2.82M
Sga Expense Q1 2025 · Mar 31, 2024 $2.82M
Rd Expense Q1 2025 · Mar 31, 2025 $4.46M
Rd Expense Q1 2025 · Mar 31, 2024 $5.62M
Net Income Q1 2025 · Mar 31, 2025 −$8.22M
Net Income Q1 2025 · Mar 31, 2024 −$11.76M
Operating Income Q1 2025 · Mar 31, 2025 −$5.21M
Operating Income Q1 2025 · Mar 31, 2024 −$8.21M
Cost Of Revenue Q1 2025 · Mar 31, 2025 $248K
Cost Of Revenue Q1 2025 · Mar 31, 2024 $0
Revenue Q1 2025 · Mar 31, 2025 $2.33M
Revenue Q1 2025 · Mar 31, 2024 $230K